Key result
Abciximab therapy during PTCA with stenting for acute myocardial infarction was associated with the development of fatal diffuse alveolar hemorrhage and ARDS in two reported cases.
Case Report (n=2)
The use of abciximab during PTCA with stenting may be associated with the rare but fatal complication of diffuse alveolar hemorrhage and ARDS.
Answers are grounded in this paper and cite their sources.
Raises caution for fatal alveolar hemorrhage with abciximab in AMI stenting; hypothesis-generating and requires confirmation in larger cohorts.
We describe two cases of diffuse alveolar hemorrhage and development of ARDS in patients who underwent percutaneous transluminal coronary angioplasty (PTCA) with stenting in whom Abciximab (ReoPro) was used in combination with other agents interfering with the hemostatic mechanism. The development of pulmonary infiltrates, associated with a fall in hemoglobin after the administration of Abciximab, should strongly suggest the possibility of diffuse alveolar hemorrhage. Physicians should be aware of the possible association between the use of Abciximab and the development of alveolar hemorrhage.
No takes yet. Share an insight, caveat, or question.
Khanlou et al. (1998) conducted a case report in Acute myocardial infarction (n=2). Abciximab was evaluated on Diffuse alveolar hemorrhage and ARDS. Abciximab therapy during PTCA with stenting for acute myocardial infarction was associated with the development of fatal diffuse alveolar hemorrhage and ARDS in two reported cases.
Synapse has enriched 10 related papers. Consider them for comparative context: